Canadian employers are facing a staggering 8.3% surge in medical plan costs for 2026, a rate more than four times faster than general inflation! This isn't just a small bump; it's a significant escalation that has health plans and businesses on high alert. While the rest of the world sees medical inflation cooling, Canada is on a different trajectory, and understanding why is crucial for everyone involved.
But here's where it gets controversial... the drivers behind this dramatic increase are complex and touch upon lifestyle, medical advancements, and even the very drugs designed to help us.
A Deep Dive into the Rising Costs
Aon's latest report paints a clear picture: Canadian employers can expect their group health costs to climb by a projected 8.3% in 2026. This is a considerable jump from the 7.4% seen in 2025. Meanwhile, general inflation is only expected to tick up slightly from 1.9% to 2.1%. This means the net medical trend – the cost increase specifically for healthcare plans beyond general inflation – will be a substantial 6.2 percentage points higher in 2026.
Globally, the average medical trend is also high at 9.8%, though slightly down from 10.0% in 2025. However, North America, encompassing both Canada and the US, is seeing a significant year-over-year increase in its gross medical trend, rising from 8.8% to 9.3%, with inflation also climbing from 2.0% to 2.4%.
What's Fueling This Healthcare Inflation?
Aon identifies a dual force at play: macroeconomic factors and clinical realities. While global inflation is generally easing, certain regions like Latin America, Africa, and the Middle East are still grappling with higher inflation, particularly those reliant on imports and susceptible to currency fluctuations and tariffs.
On the healthcare front, several key elements are driving up costs:
- Increased Utilization: People are using healthcare services more frequently.
- Growing Demand for Private Care: There's a noticeable shift towards private healthcare options.
- Aging Populations: As populations in Europe, Asia-Pacific, and Latin America age, the demand for healthcare services naturally increases.
- Advanced Medical Technologies: The rapid adoption of cutting-edge medical technologies, while beneficial, often comes with a higher price tag.
And this is the part most people miss... the specific health conditions and the medications used to treat them are playing a massive role.
The Top Clinical Culprits:
- Cardiovascular Disease: This remains the leading condition expected to drive claims in 2026 across all regions. Heart health continues to be a major concern.
- Cancer/Tumour Growth: This is the second biggest driver and a top five concern in every region. Common cancers like lung, breast, colon, rectum, and prostate are frequently cited.
- High Blood Pressure/Hypertension: This condition is a significant driver in itself and, critically, a major risk factor for many other costly diseases.
Risk Factors Contributing to the Surge:
Aon highlights hypertension as the primary risk factor, followed by physical inactivity and poor nutrition. Obesity has now climbed to fourth place. Interestingly, many countries are directly linking prescription drugs for weight loss to higher medical trends.
Diabetes is also identified as the fourth major condition impacting medical plan costs. Poor nutrition and obesity are significant contributors to diabetes, creating a compounding effect.
The Prescription Drug Predicament:
Prescription drugs have become the third-costliest component of global medical plan expenses. The emergence of GLP-1s and similar drugs, often used for weight loss, is a significant factor. These medications are now available in over 60% of surveyed countries, and employer-sponsored plans in many of these markets may cover them.
While some employers restrict coverage to diagnosed diabetes or blood sugar management, excluding weight-loss claims, this only partially mitigates the impact. Aon reports that some countries attribute as much as 10% of their medical trend to these drugs, with others seeing contributions as high as 25%!
Is this sustainable? Aon's report concludes that GLP-1s are "not appropriate for every workforce." This raises a critical question for plan sponsors: how do we balance the potential benefits of these powerful drugs with the need for evidence-based options that promote sustainable lifestyle changes and long-term health outcomes?
How Employers Are Responding to the Challenge
Faced with these escalating costs, employers are actively shifting into cost-containment mode. Aon's 2025 Global Benefits Trends Study reveals that a staggering 70% of companies now consider cost management their top strategic priority, with high medical inflation being the primary driver.
Their strategies include:
- Intensified Pricing Negotiations: About 75% of companies plan to negotiate more aggressively with existing insurers and vendors, and roughly 66% intend to conduct Request for Proposals (RFPs) to explore new options.
- Wellbeing Initiatives: These are the most prevalent tools, with 86% of countries reporting them as a leading cost mitigation measure. The focus is on preventive care to avoid more expensive interventions later and to keep employees engaged in their own health.
- Traditional Plan Design Controls: Measures like higher deductibles, copays, and referral requirements remain central to managing utilization.
- Flexible Benefit Plans: These are gaining significant traction, with two-thirds of surveyed countries expecting to use them in 2026, making them the third most common cost mitigation mechanism globally. This rise is partly attributed to a nearly 10% increase in use in APAC.
What do you think about the rising cost of healthcare? Are these employer strategies enough to curb the trend, or are we heading for a crisis? Share your thoughts in the comments below!
